160 related articles for article (PubMed ID: 16149606)
21. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
22. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
Robles-Diáz G; Aceves G; Galván E
Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of sialyl Lewis(a), sialyl Lewis(x), and sialyl Tn antigens expression levels as predictors of recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Fukushima K; Tanaka K; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
J Exp Clin Cancer Res; 2002 Mar; 21(1):107-13. PubMed ID: 12071515
[TBL] [Abstract][Full Text] [Related]
25. [Tissue polypeptide antigen (TPA)].
Sugiyama Y; Kawaguchi Y
Nihon Rinsho; 2005 Aug; 63 Suppl 8():705-7. PubMed ID: 16149617
[No Abstract] [Full Text] [Related]
26. A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers.
Kokociñska D; Jarzab B; Król R; Ziaja K; Szejbak K; Kuśmierski S
J Environ Pathol Toxicol Oncol; 1996; 15(2-4):283-7. PubMed ID: 9216823
[TBL] [Abstract][Full Text] [Related]
27. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors.
Sperti C; Pasquali C; Guolo P; Polverosi R; Liessi G; Pedrazzoli S
Cancer; 1996 Jul; 78(2):237-43. PubMed ID: 8673998
[TBL] [Abstract][Full Text] [Related]
28. [Blood CA 19-9 in the diagnosis of carcinoma of the pancreas: a critical approach].
Angonese C; Basso D; Del Favero G; Fabris C; Tremolada C; Plebani M; Burlina A; Naccarato R
Ann Ital Med Int; 1987; 2(2):138-42. PubMed ID: 3275279
[No Abstract] [Full Text] [Related]
29. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
30. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of NCC-ST-439 antigen assay detected by the monoclonal antibody as a tumor marker].
Sugano K; Okura H
Nihon Rinsho; 1990 Feb; 48 Suppl():1031-4. PubMed ID: 2192105
[No Abstract] [Full Text] [Related]
32. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero MA; Uchida E; Takasaki H; Burnett DA; Steplewski Z; Pour PM
Cancer Res; 1987 Oct; 47(20):5501-3. PubMed ID: 3308077
[TBL] [Abstract][Full Text] [Related]
33. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
34. CA 242--a step ahead.
Shahi SK; Ranga S; Bhullar C
Indian J Pathol Microbiol; 2002 Apr; 45(2):145-6. PubMed ID: 12696727
[No Abstract] [Full Text] [Related]
35. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
36. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
37. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
[TBL] [Abstract][Full Text] [Related]
38. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
39. [DU-PAN-2, SPan-1].
Motoo Y; Sawabu N
Nihon Rinsho; 2005 Aug; 63 Suppl 8():687-90. PubMed ID: 16149612
[No Abstract] [Full Text] [Related]
40. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
